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Introduction: The interpretation of equivocal Papanicolaou (Pap) smear results remains challenging, even with the
addition of the high-risk human papillomavirus test (HPV-HR). Recently, methylated zinc finger protein 582 (ZNF582)
(ZNF582m) was reported to be highly associated with cervical cancer. In this study, we compared the performance
of ZNF582m detection and HPV-HR genotyping in the triage of cervical atypical squamous cell of undetermined
significance (ASC-US) and atypical squamous cell - cannot exclude a high-grade lesion (ASC-H).
Case description: Two hundred and forty-two subjects with equivocal papanicolaou smear (Pap smear) results
were recruited in this hospital-based and case-controlled study. The residual cervical cells in liquid-based cytological
test (LBC) containers were used for genomic DNA extraction and then for ZNF582m and HPV-HR detection. The level
of ZNF582m was quantified by real-time methylation-specific PCR after bisulfite conversion. The HPV-HR test was
performed by using a nested multiplex PCR (NMPCR) assay that combines degenerate E6/E7 consensus primers
and HPV type-specific primers.
Discussion and evaluation: Significant associations were observed between ZNF582m and the risk of cervical
intraepithelial neoplasia grade 3 or higher (CIN3+; odds ratio = 15.52, 95% confidence interval (CI): 7.73 to 31.18).
The sensitivity and specificity of ZNF582m for women with CIN3+ were 82.43% and 76.79%, respectively. High
sensitivity (99.33%) but low specificity (38.76%) was observed for HPV-HR. When combining both positive results
of ZNF582m and HPV-HR, the sensitivity and specificity were 82.43% and 81.55%, respectively. The sensitivity and
specificity of ZNF582m or HPV-16/18 were 89.19% and 70.24%, respectively. However, the sensitivity and specificity of
ZNF582m combined with HPV-16/18 (both ZNF582m and HPV-16/18 positive results) were 59.46% and 94.64%, respectively.
Conclusions: ZNF582m provides a promising triage tool for women with ASC.
To effectively manage ASC patients, a new strategy co-testing for ZNF582m and HPV-16/18 genotyping was proposed. This
strategy could reduce the number of patients referred for colposcopic examination and thus provide a feasible follow-up
solution in the regions where colposcopy is not readily available. This strategy could also prevent women from
experiencing unnecessary anxiety caused by HPV-HR.
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Cervical cancer is the fourth most common cancer that af-
fects women worldwide. In China, approximately 58,000
new cases and 20,000 deaths were documented in 2005
[1-5]. Screening with the cytological test developed by
George Papnicolaou (the Pap test) has led to a significant
reduction in the incidence of cervical cancer over the past
few decades. However, the optimal treatment regimen for
women with atypical squamous cell (ASC) is not well
established. In the case of an ASC smear result, a patholo-
gist has to specify the type as either atypical squamous cell
of undetermined significance (ASC-US) or cannot exclude
a high-grade lesion (ASC-H). ASC-US and ASC-H need
to be closely monitored to prevent the development of
high-grade squamous intraepithelial lesions (HSIL). Hy-
brid capture 2 human papillomavirus (HC2 HPV) testing
has been widely adopted for the triage of patients with
ASC-US [6]. The recommendation for ASC-H is colpos-
copy [7]. The sensitivity of HPV testing is good; however,
the high prevalence of transient HPV infections limits the
specificity of this approach, resulting in high number of
colposcopic referrals and unnecessary anxiety for women.
Thus, there is a need for other markers, which have both
high sensitivity and specificity [8-10].
The mechanisms of pathogenesis in cervical cancer
are not entirely clear. Hypermethylation of CpG sites in
promoter regions silences the transcription of tumor
suppressor genes and is an early and crucial event in
cancer development [11-13]. Inactivation of tumor sup-
pressor genes and activation of oncogenes also play a
significant role in carcinogenesis, caused by genetic and
epigenetic alterations. Various genome-wide approaches
have been used to discover new abnormally methylated
genes for many cancers. For example, candidate methyl-
ated genes have been selected, including COL25A1 and
KATNAL2, which showed increased methylation during
progression in high-grade cervical intraepithelial neoplasia
(CIN) lesions, to screen for the early detection of cervical
cancer [14,15]. The advanced concept of using DNA
methylation as a biomarker for cervical cancer screening
is appealing [16-19], and several hypermethylated genes
have already been identified [20]. Among them, zinc finger
protein 582 (ZNF582) possesses great clinical potential
[21]. ZNF582 is located on chromosome 19q13.43, which
contains one KRAB-A-B domain and nine zinc-finger
motifs. A recent study of acute myeloid leukemia revealed
that aberrant methylation of ZNF582 is consistent in differ-
ent disease subtypes, especially in the promoter region. Al-
though the biological function of ZNF582 is not yet well
characterized, a group in Taiwan found similar associations
for cervical cancer and adenocarcinoma with ZNF582 using
cervical scrapings. Recently, one study also revealed that
hypermethylated ZNF582 (methylated ZNF582 (ZNF582m))
performs well as a marker for detecting grade III or highercervical intraepithelial neoplasia (CIN3+) with 73% sen-
sitivity and 71% specificity for women with low-grade
squamous intraepithelial lesions [21-23].
In the present study, we examined the performance of
methylated ZNF582 testing (ZNF582m) for the triage of
ASC-US and ASC-H cervical scrapings and compared
the results with those of HPV DNA testing.
Case description
Patient recruitment
The study was approved by the Department of Clinical
Pharmacology, Xiangya Hospital, Central South University,
People’s Republic of China. During the period between
December 2011 and April 2013, women referred for a
colposcopic examination were invited to participate in
the study. The eligible women were sexually active,
scheduled to undergo a liquid-based cytology test
(LBC) within a week, not pregnant, possessed an intact
uterus, and no history of treatment for CIN or cervical
cancer. The exclusion criteria included women who
had a history of cancer related to the reproductive
tract, underwent therapy for cervical lesions, received
the HPV vaccination, or were currently pregnant.
Standard guidelines for the management and treatment
of cervical neoplasia were followed in all subjects [24].
The cytology results were classified according to the
2001 Bethesda System [25].
After signing the informed consent, patients immedi-
ately received the colposcopic examination and biopsy.
The follow-up clinical information was collected. When
the biopsy results revealed moderate to severe dysplasia or
worse, patients underwent conization or major surgery.
The final diagnosis was based on the results of tissue-
proven pathology, rather than on the LBC results. To
ensure the quality control of the diagnosis, two expert
cytologists and two pathologists independently read or
reviewed the cytology and histology slides, respectively.
All of the patient recruitment and clinical information
collection processes were periodically monitored and
good clinical practice (GCP) guidelines were followed.
Specimen collection and DNA preparation
All of the patients had LBC testing before receiving the
colposcopic examination. After the informed consent
was signed, the LBC containers (Hospitex Diagnostics
SRL, Sesto Fiorentino, Italy) were picked up from the
Cytology Department, and the residual cervical cells
were used for HPV typing and detection of methylated
ZNF582. All of the molecular tests were performed at the
Institute of Clinical Pharmacology, Hunan Key Laboratory
of Pharmacogenetics, China, following GLP guidelines. The
cells were centrifuged and stored in phosphate-buffered sa-
line (PBS) solution at −20°C from the day of collection, and
the assays were finished within 6 months. Genomic DNA
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QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s protocol. A BioSpec-nano
spectrophotometer (Shimadzu Corporation, Tokyo, Japan)
was used to quantify the amount of extracted DNA.
DNA methylation tests
For the DNA methylation tests, quantitative methylation-
specific PCR (QMSP) using TaqMan-based technologies
was performed using the Lightcycler LC480 real-time PCR
system (Roche Applied Science, Penzberg, Germany).
Briefly, 500 ng of gDNA was subjected to bisulfite con-
version using the EZ DNA Methylation-Gold™ Kit
(Zymo Research, CA,USA), according to the manufac-
turer’s recommendations.
The methylation levels of ZNF582 were then determined
using the qPCR kits developed by iStat Biomedical located
in Taiwan. The type II collagen gene (COL2A) was de-
signed as the internal reference and tested with each spe-
cimen. The crossing point (Cp) value for COL2A, which is
also the validity indicator of the test, should not be larger
than 35. The PCR cycling conditions consisted of an initial
incubation at 95°C for 10 min, followed by 50 cycles of de-
naturation at 95°C for 10 s, and annealing/extension at 60°
C for 40 s. Fluorescence data were collected during the
annealing/extension step for determination of the Cp.
For each sample, two Cp values were obtained: one
from the target gene and another from COL2A. The
DNA methylation level was subsequently determined
from the difference between the two Cp values (delta
Cp = CpZNF582 - CpCOL2A). ZNF582 was deemed to be
hypermethylated or positive if the delta Cp was smaller
than 13 (the cut-off value). The registered CaSki and
A375 cancer cell lines were used as the methylation
and no-methylation controls to ensure the quality of bi-
sulfite conversion and qPCR processes. Representative
positive and negative QMSP results are shown in Figure 1.
Laboratory methods for HPV DNA amplification and
genotyping
High-risk human papillomavirus (HPV-HR) typing was
performed using a nested multiplex PCR (NMPCR) assay
that combines degenerate E6/E7 consensus primers and
type-specific primers. The identification of HPV-HR was
achieved by determining the size of the nested PCR ampli-
fication product [26].
Statistical analysis
The cut-off values for ZNF582m were generated from
the first 100 subjects, including 50 subjects with normal
Pap test results and 50 subjects with abnormal Pap test
results. Receiver operating characteristic (ROC) curves
were generated, and the area under the ROC curve(AUC) was calculated for the detection of the CIN3+
lesions.
SAS software (version 9.2) was used for all statistical
analyses (SAS Institute, Ltd., Cary, NC, USA). The chi-
square test was used to analyze the status of methylated
ZNF582 or HPV typing in different combinations. Fisher’s
exact test was used for the small number data, for ex-
ample, age under 30 group analysis. For the final analysis,
the sensitivity and specificity with a 95% confidence inter-
val (CI) for grade CIN3 lesions or worse were obtained.
All differences were considered two-sided and statistically
significant at P < 0.05.
Discussion and evaluation
Establishment of routine Pap screening has resulted in a
significant decrease in cervical cancer deaths. In China,
ASC, including ASC-US and ASC-H, were reported in
approximately 10% of papanicolaou smear (Pap smears)
[27]. The large number of ASC patients referred for col-
poscopic examination and follow-up could be an extra
burden. In conjunction with the currently available tests,
molecular diagnostic tests that can assist in the diagnosis
of cancer and that have both a high sensitivity and high
specificity would be useful because they would be more
accurate than Pap tests alone. Recent guidelines in the
USA recommend that adult women with an ASC-US
Pap result either have the Pap test repeated at 6 and
12 months, or have an HPV-HR DNA test. In China,
repeated follow-up is impractical and time-consuming be-
cause many areas do not have sufficient medical resources
to perform additional examinations. Another option is to
send ASC patients for colposcopy, but colposcopy may
not be available in the areas where patients reside thus
prohibiting or delaying the diagnosis. Moreover, colpos-
copy is more invasive and causes anxiety to many women.
Because of the high sensitivity, triage of ASC-US with
HPV-HR has been suggested in the cervical screening
guidelines. This strategy provides the advantage of missing
fewer cases of the severe disease state [28]. However, the
low specificity still leads to approximately 50% of women
with ASC-US being referred for colposcopy [29]. A similar
trend was observed in the present study. The sensitivity
and specificity of HPV-HR for detecting CIN3+ were
99.33% and 38.76%, respectively. Seventy-three percent
(177/242) of the women with an ASC-US or ASC-H result
were positive for HPV-HR, but 61.3% of them had a histo-
logical result of CIN2, CIN1, or normal, which is not indi-
cative of a referral for a colposcopic examination. Thus,
the HPV-HR test is limited by its low specificity.
In 2012, the American Cancer Society proposed new
screening guidelines that included using age-adjusted
screening methodologies as well as cytological and HPV
co-testing. HPV 16 and 18 typing has been recommended
for HPV-HR-positive women [30]. However, geographic
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Asia, in addition to HPV types 16 and 18, types 52 and 58
are frequently observed in patients with invasive cervical
cancers [31-33]. Similar trends were also observed in the
present study even though the test subjects were only lim-
ited to women with ASC. In CIN3+ lesions (N = 74), HPV
16 (55.4%) and HPV 52 (31.1%) were the most common
types, followed by HPV 18 (13.5%), HPV 58 (12.2%), and
HPV 33 (9.4%). Among the high percentage of HPV 16
and/or 52 in the CIN3 lesions, the sensitivity, specificity,
and accuracy are 74.32%, 73.81%, and 73.97%, respectively.Figure 1 Representative positive and negative ZNF582 methylation detecti
and COL2A (labeled with VIC) were detected simultaneously. Fluorescence da
of the crossing point (Cp). The amplification curve for ZNF582 is shown in pan
indicates the crossing point, and the x-axis value is the so-called Cp value. The
smaller ΔCp indicates a higher degree of methylation detected in the testing
ΔCp was smaller than 13 (the cut-off value). The blue arrow is Cp value of ZN
ZNF582, zinc finger protein 582; ZNF582m, methylated ZNF582.Therefore, the combination of Pap smear and HPV-16/18
typing is not sufficiently accurate for cervical cancer triage
in this study.
ZNF582m has been found to possess clinical potential
for the detection of cancer. For example, the frequency
of methylated ZNF582 detection was 100% in SCC tis-
sue. Clinically, ZNF582m has demonstrated 70% sensi-
tivity and 82% specificity for CIN3+ lesions in a
Taiwanese case-control cohort. For triage of LSIL,
ZNF582m also has good sensitivity and specificity with
values of 73% and 71%, respectively. Moreover, theon by real-time PCR. For each specimen, ZNF582m (labeled with FAM)
ta were collected during the annealing/extension step for determination
el (A) and the control COL2A gene is shown in panel (B). The blue arrow
ΔCp is the difference between Cp values for ZNF582m and COL2A. A
sample. ZNF582 was deemed to be hypermethylated (or positive) if the
F582m and the green arrow is the un-methylated ZNF582m in panel (A).
Table 2 Characteristics and histological results of the
study subjects
Histological results Total
Normal CIN 1 CIN 2 CIN 3/CI SCC/AC
Number of subjects
N 109 23 36 45 29 242
(%) (45.04%) (9.50%) (14.88%) (18.60%) (11.98%) (100%)
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cervical adenocarcinoma, which has been difficult to
diagnose.
In triage of the ASC group, CADM1/MAL, WT1, and
other methylation genes have been reported [34]. The
present study has proposed a new strategy: co-testing
for ZNF582m and HPV-16/18, in which the patients
negative for ZNF582m undergo HPV-16/18 genotyping.
As mentioned, the sensitivity, specificity, and accuracy of
the co-test are 89.19%, 70.24%, and 76.03%, respectively.
The colposcopy referral rate of the co-test is 47.9%,
which is 25.2% less than that of HPV-HR alone. Al-
though eight cases of CIN3+ (10.81%) were missed,
nearly 100% of the women with SCC were successfully
diagnosed and treated (Table 1). It is also known that
the cumulative actuarial rate of progression from CIN3
(severe dysplasia) to CIS or worse is 12% in 4 to
24 months [35,36]. Thus, for patients with ASC un-
detected by the co-test, a regular follow-up Pap test
would be highly recommended. Thus, the progression of
the lesion for the eight women with undetected CIN3
would be closely monitored. This triage model would
greatly reduce the cost and increase the accuracy for pa-
tients residing in countries with limited resources for
colposcopy, such as China.
The subjects were recruited at the colposcopic examin-
ation room. As mentioned, women had results of abnormal
pap, inflammation syndrome, cervical erosion, bedding
syndromes, or suspected cervical cancer, and these women
would be referred to have a colposcopic examination. In
our cohort, >90% of women had inflammation syndrome
with positive HPV-HR, which correlate with high percent-
age of CIN2+ (~45%) observed. Although it is known that
heterogeneous etiology for cancers and the equivocal
nature of ASC, the significance of ZNF582m in cancer de-
tection was still being observed.
Characteristics of subjects and colposcopic biopsy results
From November 2011 to March 2013, 242 women were
































CIN, cervical intraepithelial neoplasia; HPV-HR, high-risk human papillomavirus;
SCC, squamous cell carcinoma; ZNF582m, methylated ZNF582.of the subjects are shown in Table 2. Generally, when
women received results of an abnormal Pap, cervical ero-
sion, or suspected cervical cancer, they would be referred to
colposcopic examination room from the gynecological out-
patient department (OPD). There were 199 women who
had ASC-US and 43 who had ASC-H based on the LBC
test. The histological and cytological results of the 242
women are shown in Table 2. In total, the colposcopy and
biopsy results revealed normal histology in 109 (45.04%)
patients, CIN1 in 23 (9.50%) patients, CIN2 in 36 (14.87%)
patients, CIN3 in 39 (16.11%) patients, carcinoma in situ
(CIS) in 6 (2.47%) patients, and invasive carcinoma in 29
(11.98%) patients. Thus, 30.6% (74 of 242) of the total pa-
tients had a histological finding of CIN3 or worse (CIN3+).
Specifically, 22.1% and 70% of the patients had CIN3+ in
the ASC-US and ASC-H groups, respectively.
Molecular test results in the detection of CIN3+: ZNF582m
and HPV genotyping
The distribution of the molecular tests for different levels
of disease severity is listed in Table 2. Table 3 shows the
results of the sensitivity, specificity, and accuracy for dif-
ferent molecular tests or combinations of molecular tests(%) (51.75%) (10.05%) (16.08%) (14.57%) (7.53%) (100%)
ASC-H 6 3 4 16 14 43
(%) (13.95%) (6.97%) (9.30%) (37.20%) (32.55%) (100%)
ZNF582m
Number 18 8 13 36 25 100
(%) (16.51%) (34.78%) (36.11%) (80.00%) (86.20%) (41.32%)
HPV-HR
Number 57 13 33 45 29 177
(%) (52.29%) (56.52%) (91.67%) (100%) (100%) (73.14%)
AC, adenocarcinoma of the uterine cervix; ASC-H, atypical squamous cells,
high-grade squamous intraepithelial lesions could not be excluded; ASC-US,
atypical squamous cells of undetermined significance; CIN, cervical intraepithelial
neoplasia; CIS, carcinoma in situ; HPV-HR, high risk human papillomavirus; SCC,
squamous cell carcinoma.
Table 3 The performance of combinations of ZNF582m and HPV tests in detecting CIN3+ in ASC
Tests Sensitivity (%) Specificity (%) Accuracy (%) OR (95% CI) P value
All ages (N = 242)
ZNF582m 82.43 76.79 78.52 15.52 (7.73 to 31.18) <0.001
HPV-HR 99.33 38.76 57.37 - <0.001
HPV-16/18 66.22 88.10 81.41 14.50 (7.42 to 28.37) <0.001
ZNF582m or HPV-16/18 89.19 70.24 76.03 19.47 (8.71 to 43.54) <0.001
ZNF582m or HPV-16/18/52/58 95.95 48.81 63.22 14.79 (6.39 to 34.19) <0.001
ZNF582m or HPV-HR 99.33 34.02 54.10 76.84 (4.68 to 1262.62) 0.002
ZNF582m and HPV-HR 82.43 81.55 81.82 - <0.001
ZNF582m and HPV-16/18 59.46 94.64 83.88 25.91 (11.45 to 58.61) <0.001
Age under 30 (N = 31) Sensitivity (%) Specificity (%) Accuracy (%) OR (95% CI) P value
ZNF582m 75.00 81.48 80.65 13.20 (1.12 to 154.92) 0.043
HPV-HR 90.00 41.07 48.49 - 0.233
HPV-16/18 75.00 92.59 90.33 37.50 (2.56 to 548.36) 0.009
ZNF582m or HPV-16/18 75.00 77.78 77.42 10.50 (0.92 to 120.26) 0.063
ZNF582m or HPV-HR 90.00 37.50 45.46 - 0.274
ZNF582m and HPV-HR 75.00 85.19 83.87 17.25 (1.42 to 210.12) 0.028
ZNF582m and HPV-16/18 75.00 96.30 93.55 78.00 (3.81 to 1595.87) 0.004
Postmenopausal Women Sensitivity (%) Specificity (%) Accuracy (%) OR (95% CI) P value
ZNF582m 88.89 69.77 75.41 18.46 (3.70 to 92.14) <0.001
HPV-HR 97.37 48.86 63.49 - 0.001
HPV-16/18 88.89 86.05 86.89 49.33 (8.97 to 271.23) <0.001
ZNF582m or HPV-16/18 97.37 62.50 73.02 - <0.001
ZNF582m or HPV-HR 97.37 44.32 60.32 - 0.001
ZNF582m and HPV-HR 88.89 74.42 78.69 23.27 (4.60 to 117.81) <0.001
ZNF582m and HPV-16/18 77.78 93.02 88.52 46.67 (9.27 to 234.86) <0.001
P values determined by chi-square test or Fisher’s exact test; CI, confidence interval; HPV, human papillomavirus; HPV-HR, high-risk human papillomavirus; OR, odds
ratio for CIN3 +; ZNF582m, methylated ZNF582.
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Among the 242 ASC subjects, 41% were positive for
ZNF582m. The sensitivity, specificity, and accuracy of
ZNF582m in the identification of CIN3+ lesion were
82.43%, 76.79%, and 78.51%, respectively. However, when
the CIN2 or more severe neoplasms were targeted, the
sensitivity and accuracy of ZNF582m was decreased to
67.27% and 74.38%, respectively, but the specificity was in-
creased to 80.30%. Among women less than 30 years old
with ASC, the sensitivity, specificity, and accuracy of
ZNF582m in the identification of a CIN3+ lesion were
75.00%, 81.48%, and 80.65%, respectively. For postmeno-
pausal women with ASC, the sensitivity, specificity, and
accuracy were 88.89%, 69.77%, and 75.41%, respectively.
The HPV typing indicated that 177 (73.14%) patients
were positive for HPV-HR. The most common types of
HPV were HPV 16 (23.14%), HPV 52 (23.14%), HPV 58
(14.88%), HPV 68 (7.85%), HPV 33 (7.44%), and HPV 18
(6.05%). The sensitivity and specificity of HPV-HR in
identifying CIN3+ were 99.33% and 38.76%, respectively.The percentage of patients who were positive for HPV-
16/18 and who had CIN3+ was 66.22% (49 of 74). The
prevalence of HPV-16/18 in patients whose tissue was
pathologically normal, CIN1, CIN2, CIN3/CIS, or squa-
mous cell carcinoma (SCC) was 7.34%, 17.39%, 22.22%,
55.56%, and 82.76%, respectively.
The results for ZNF582m combined with different
HPV genotyping assays are interesting. The sensitivity of
ZNF582m combined with HPV-HR, HPV-16/18/52/58,
or HPV-16/18 was 99.33%, 95.98%, or 89.19%, respect-
ively, but the specificity was increased with values of
34.02%, 48.81%, and 70.24%, respectively.
Colposcopy referral rate: the performance of ZNF582m
and HPV genotyping in the triage of ASC
Colposcopy is a diagnostic procedure performed by a
physician to examine the cervix, vagina, and vulva care-
fully for signs of disease. Due to the high cost and insuffi-
cient availability of colposcopy, it is desirable to reduce the
number of colposcopy referrals while still examining
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CIS, or SCC. Our results indicated that the referral rate
for colposcopy for ZNF582m alone, HPV-HR alone, and
ZNF582m, or HPV-16/18 are 41%, 73.1%, and 47.9% re-
spectively (Table 1). Previous research has recommended
triage procedures using HPV-HR followed by gene methy-
lation screening [34]. Using HPV-HR testing as triage iden-
tified no CIN3 and SCC results in the study but the referral
rate for colposcopy is 73.1%. If triaged using ZNF582m test-
ing alone, the colposcopy referral would therefore reduce
31.8% compared to that of HPV-HR. However, only 61 out
of the 74 women with CIN3+ and 4 SCC results would be
detected. As a result, no treatment would be given to 17
women, who would be in a severe disease stage, especially
the four with SCC. To avoid not detecting the severe cases,
we have proposed a new strategy to manage ASC patients
(Figure 2). This clinical flowchart has incorporated the
ZNF582m and HPV testing into the procedures. Co-testing
for ZNF582m and HPV-16/18 would therefore reduce 61Figure 2 The recommended management of abnormal cervical cytology (
squamous cells cannot exclude high-grade squamous intraepithelial lesion
cervical intraepithelial neoplasia 2; HPV, human papillomavirus-16/18; ZNF58cases (25.21%) from colposcopy referral (when compared
with HPV-HR), yet none of the SCC cases would be missed
(Figure 2).
Conclusions
To the best of our knowledge, the present study is the
first to discuss the involvement of ZNF582m in the ASC
group and to consider using the combination of HPV re-
sults and methylation markers in the triage of colposcopic
referral. It is also the first to compare HPV genotyping
and ZNF582m in the triage of women with ASC Pap smear
results. Our results showed that ZNF582m could be a
promising triage technique for women with ASC. We have
recommended a new management strategy of abnormal
cervical cytology (Pap smear) illustrated in a flowchart.
The present study did have some limitations. The subjects
were recruited at the colposcopic examination room.
Other limitations include using a smaller sample sizes and
a lack of extensive long-term follow-up information.Pap smear): a flowchart with methylated ZNF582m. ASC-H, atypical
; ASC-US, atypical squamous cells of undetermined significance; CIN,
2, zinc finger protein 582; ZNF582m, methylated ZNF582.
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followed by HP-V16/18 testing could help to reduce the
number of patients with ASC being referred for colpos-
copy. This could reduce the logistics of obtaining follow-
up care, especially in regions where colposcopy is not eas-
ily available, which could have a significant impact on pub-
lic health.
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